ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 治療可能な認知症としてのアルツハイマー病
文献概要
超高齢社会にあって，アルツハイマー病に対する疾患修飾療法の開発が急務とされてきたが，2023年になってようやく，抗アミロイド抗体薬が正式に医薬品として承認されるようになってきた。本論では，抗アミロイド抗体薬のうち特にaducanumab，レカネマブ，donanemab，remternetug，trontinemabについてこれまでの開発・臨床実用の状況，課題や今後の展望などについて概説する。
参考文献
1）Jack CR Jr: Advances in Alzheimer's disease research over the past two decades. Lancet Neurol 21: 866-869, 2022
2）二宮利治: 内閣官房認知症施策推進関係者会議（第2回）資料9認知症及び軽度認知障害の有病率調査並びに将来推計に関する研究, 2024 https://www.cas.go.jp/jp/seisaku/ninchisho_kankeisha/dai2/gijisidai.html（最終閲覧日: 2024年6月13日）
3）佐藤謙一郎: 抗アミロイドβ抗体薬の開発と治験結果. カレントテラピー42: 184-189, 2024
4）佐藤謙一郎, 岩坪威: 話題のくすり レカネマブ. 日病薬誌60: 271-278, 2024
5）中島紗樹, 佐藤謙一郎: 認知症の新規治療薬. Vita 41: 34-38, 2024
6）Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002
7）Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, et al: Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12: 207-216, 2013
8）Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, et al: Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146: 4414-4424, 2023
9）Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, et al: Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81: 49-60, 2014
10）Knopman DS, Jones DT, Greicius MD: Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement 17: 696-701, 2021
11）Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, et al: Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 79: 13-21, 2022
12）Phillips KA: CMS coverage with evidence development-challenges and opportunities for improvement. JAMA Health Forum 3: e223061, 2022［doi: 10.1001/jamahealthforum.2022.3061］
13）Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, et al: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 13: 80, 2021［doi: 10.1186/s13195-022-00995-9］
14）McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, et al: Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther 14: 191, 2022［doi: 10.1186/s13195-022-01124-2］
15）van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, et al: Lecanemab in early Alzheimer's disease. N Engl J Med 388: 9-21, 2023
16）Honig LS, Barakos J, Dhadda S, Kanekiyo M, Reyderman L, et al: ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. Alzheimers Dement (N Y) 9: e12377, 2023［doi: 10.1002/trc2.12377］
17）Tahami Monfared AA, Tafazzoli A, Chavan A, Ye W, Zhang Q: The potential economic value of lecanemab in patients with early Alzheimer's disease using simulation modeling. Neurol Ther 11: 1285-1307, 2022
18）Igarashi A, Azuma MK, Zhang Q, Ye W, Sardesai A, et al: Predicting the societal value of lecanemab in early Alzheimer's disease in Japan: a patient-level simulation. Neurol Ther 12: 1133-1157, 2023
19）Wright AC, Lin GA, Whittington MD, Agboola F, Herron-Smith S, et al: The effectiveness and value of lecanemab for early Alzheimer disease: a summary from the institute for clinical and economic review's California Technology Assessment Forum. J Manag Care Spec Pharm 29: 1078-1083, 2023
20）Burke JF, Kerber KA, Langa KM, Albin RL, Kotagal V: Lecanemab: looking before we leap. Neurology 101: 661-665, 2023
21）レケンビ点滴静注200mg/レケンビ点滴静注500mg 添付文書 https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/1190408（最終閲覧日: 2024年6月13日）
22）医薬品医療機器総合機構: 最適使用推進ガイドライン（医薬品）: レカネマブ（遺伝子組み換え）, 2023 https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0028.html（最終閲覧日: 2024年6月13日）
23）日本医療研究開発機構: 公募情報 令和5年度「認知症研究開発事業（2次公募）」の採択課題について: アルツハイマー病疾患修飾薬全国臨床レジストリの構築と解析, 2024 https://www.amed.go.jp/koubo/14/03/1403C_00082.html（最終閲覧日: 2024年6月13日）
24）Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, et al: Donanemab in early Alzheimer's disease. N Engl J Med 384: 1691-1704, 2021
25）Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, et al: Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330: 512-527, 2023
26）Tipton PW: Updates on pharmacological treatment for Alzheimer's disease. Neurol Neurochir Pol 58: 150-160, 2024
27）AlzForum: Unlocking blood-brain barrier boosts immunotherapy efficacy, lowers ARIA, 2023 https://www.alzforum.org/news/conference-coverage/unlocking-blood-brain-barrier-boosts-immunotherapy-efficacy-lowers-aria（最終閲覧日: 2024年6月13日）
掲載誌情報
